Skip to main content

Table 1 Characteristics of patients

From: Correlation between NK function and response to trastuzumab in metastatic breast cancer patients

Patient # Type of mts No. of mts Response
999 Visceral1 > 3 DP
1025 Visceral < 3 CR
1080 Visceral > 3 DP
1081 Visceral < 3 DP
1083 Visceral > 3 PR
1095 Visceral < 3 CR
1125 Visceral > 3 DP
1126 Visceral < 3 SD
1102 Non-visceral2 > 3 CR
1103 Non-visceral < 3 SD
1110 Non-visceral < 3 CR
1121 Non-visceral > 3 DP
1123 Non-visceral < 3 SD
1124 Non-visceral < 3 CR
1019 Mixed3 > 3 PR
1020 Mixed > 3 SD
1021 Mixed > 3 PR
1026 Mixed > 3 DP
1082 Mixed > 3 DP
1104 Mixed > 3 PR
1105 Mixed > 3 SD
1116 Mixed > 3 DP
1270 Visceral < 3 RC
1276 Mixed > 3 PR
1279 Non-visceral < 3 PR
1280 Visceral > 3 PD
  1. 1Visceral mts: liver, lungs, CNS
  2. 2Non-visceral metastases (mts): bones, locoregional lymph nodes, skin
  3. 3Mixed: visceral and non-visceral
  4. DP: disease progression; CR: complete remission; PR: partial remission; SD: stable disease.